Filing Flows › UroGen Pharma (URGN) › Q3 2026 › vs Q2 2026
UroGen Pharma (URGN) Q3 2026 vs Q2 2026 (quarter over quarter)
UroGen Pharma's revenue rose $16.5M (+23%) from $72.5M in Q2 2026 to $89.0M in Q3 2026. The biggest changes: Zusduri +$17.6M (+35%); Jelmyto −$1.1M (-5%).
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Zusduri | $68.0M | $50.4M | $17.6M | +35% |
| Jelmyto | $21.0M | $22.0M | −$1.1M | -5% |
| Revenue | $89.0M | $72.5M | $16.5M | +23% |
| Net loss | $1.5M | $14.4M | −$12.9M | -90% |
| Costs & expenses | $90.5M | $86.8M | $3.7M | +4% |
| Operating costs | $80.7M | $72.3M | $8.3M | +12% |
| Interest & other, net | $8.8M | $8.8M | −$58K | -0.7% |
| Income tax | $1.0M | $5.6M | −$4.6M | -82% |
| Cost of revenue | $7.5M | $6.6M | $930K | +14% |
| Research & development | $26.0M | $17.3M | $8.6M | +50% |
| SG&A | $47.2M | $48.4M | −$1.2M | -3% |
| Operating cash sources | $21.5M | $38.4M | −$16.9M | -44% |
| Depreciation & amortization | $100K | $100K | $0 | 0% |
| Share-based compensation | $6.2M | $5.3M | $915K | +17% |
| Cash used in operations | $15.2M | $33.0M | −$17.8M | -54% |
| Net loss absorbed | $1.5M | $14.4M | −$12.9M | -90% |
| Working capital & other | $20.1M | $24.1M | −$4.0M | -17% |
Questions
How much did UroGen Pharma's revenue grow quarter over quarter in Q3 2026?
UroGen Pharma's revenue rose $16.5M (+23%) from $72.5M in Q2 2026 to $89.0M in Q3 2026.
What drove UroGen Pharma's revenue change in Q3 2026?
Zusduri +$17.6M (+35%); Jelmyto −$1.1M (-5%).